MARKET

LIXT

LIXT

Lixte Biotechnology Hldgs Inc
NASDAQ
3.710
+0.410
+12.42%
After Hours: 3.510 -0.2 -5.39% 16:06 07/15 EDT
OPEN
3.300
PREV CLOSE
3.300
HIGH
4.175
LOW
3.300
VOLUME
564.87K
TURNOVER
--
52 WEEK HIGH
4.450
52 WEEK LOW
0.6400
MARKET CAP
10.23M
P/E (TTM)
-2.5595
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 14h ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 1d ago
Weekly Report: what happened at LIXT last week (0707-0711)?
Weekly Report · 1d ago
Lixte’s LB100 Clinical Trials Validated by Nature
TipRanks · 4d ago
Lixte Biotechnology Unveils Promising Study Results: LB-100 Shows Enhanced Immunotherapy Response in Ovarian and Colorectal Cancer Trials
Reuters · 4d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 5d ago
Lixte Biotechnology announces publication in Nature journal on LB100 trials
TipRanks · 6d ago
LIXTE Biotechnology's LB100 Highlighted In 'Nature' Study Showing PP2A Inhibition Enhances Immunotherapy Response In Ovarian And Colorectal Cancers
Benzinga · 6d ago
More
About LIXT
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company’s inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. It is focused on the clinical development of a specific protein phosphatase inhibitor, LB-100. The LB-100 series has activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue.

Webull offers Lixte Biotechnology Holdings Inc stock information, including NASDAQ: LIXT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LIXT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LIXT stock methods without spending real money on the virtual paper trading platform.